Literature DB >> 7492334

Characterization of des-(741-1668)-factor VIII, a single-chain factor VIII variant with a fusion site susceptible to proteolysis by thrombin and factor Xa.

M J Donath1, R T de Laaf, P T Biessels, P J Lenting, J W van de Loo, J A van Mourik, J Voorberg, K Mertens.   

Abstract

A factor VIII variant has been characterized in which the heavy chain is directly fused to the light chain. Des-(741-1668)-factor VIII lacks the processing site at Arg1648, as Arg740 of the heavy chain is fused to Ser1669 of the light chain. The sequence of the fusion site is similar to that of other cleavage sites in factor VIII. The fusion site of des-(741-1668)-factor VIII was readily cleaved by both thrombin and factor Xa, and the same result was obtained for heavy chain cleavage. In contrast, des-(741-1668)-factor VIII cleavage by thrombin at position Arg1689 proceeded at a lower rate than the analogous cleavage by factor Xa, which presumably takes place at position Arg1721. The rate of cleavage at position Arg1689 by thrombin was also lower than that at the other processing sites. When des-(741-1668)-factor VIII was activated by thrombin, initial rates of factor Xa formation were similar to the rates obtained when plasma-derived factor VIII was activated by thrombin or factor Xa. Remarkably, activation of des-(741-1668)-factor VIII proceeded at a higher rate by factor Xa than by thrombin. These results indicate that factor VIII activation is strongly associated with cleavage at position Arg1689 or Arg1721. For the interaction between des-(741-1668)-factor VIII and von Willebrand factor, a Kd value of (0.8 +/- 0.3) x 10(-10) M was determined, which is similar to that of heterodimeric factor VIII. The affinity of single-chain des-(741-1668)-factor VIII for factor IXa was found to be 27 +/- 6 nM. The in vivo recovery and half-life of des-(741-1668)-factor VIII were assessed in guinea pigs. Upon infusion of des-(741-1668)-factor VIII at a dosage of 50 units/kg body weight, a rise of 1.0 +/- 0.3 unit/ml in factor VIII activity was obtained. The same recovery was determined for wild-type factor VIII. The half-life of des-(741-1668)-factor VIII was found to be 3 +/- 1 h, compared with 4 +/- 2 h for heterodimeric recombinant factor VIII. In conclusion, des-(741-1668)-factor VIII displays normal activity, is readily cleaved by thrombin and factor Xa at its fusion site, binds with high affinity to von Willebrand factor and factor IXa, and behaves like heterodimeric recombinant factor VIII in guinea pigs. By virtue of these properties, des-(741-1668)-factor VIII may prove useful for the treatment of bleeding episodes in patients with haemophilia A.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7492334      PMCID: PMC1136225          DOI: 10.1042/bj3120049

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  37 in total

1.  Detection of the carrier state in hereditary coagulation disorders. I.

Authors:  J J Veltkamp; E F Drion; E A Loeliger
Journal:  Thromb Diath Haemorrh       Date:  1968-03-31

2.  Structure of human factor VIII.

Authors:  G A Vehar; B Keyt; D Eaton; H Rodriguez; D P O'Brien; F Rotblat; H Oppermann; R Keck; W I Wood; R N Harkins; E G Tuddenham; R M Lawn; D J Capon
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

3.  Molecular cloning of a cDNA encoding human antihaemophilic factor.

Authors:  J J Toole; J L Knopf; J M Wozney; L A Sultzman; J L Buecker; D D Pittman; R J Kaufman; E Brown; C Shoemaker; E C Orr
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

4.  Activation of human coagulation factor VIII by activated factor X, the common product of the intrinsic and the extrinsic pathway of blood coagulation.

Authors:  K Mertens; R M Bertina
Journal:  Thromb Haemost       Date:  1982-04-30       Impact factor: 5.249

5.  Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium.

Authors:  H V Stel; K S Sakariassen; B J Scholte; E C Veerman; T H van der Kwast; P G de Groot; J J Sixma; J A van Mourik
Journal:  Blood       Date:  1984-06       Impact factor: 22.113

6.  Purification of human factor VIII:C and its characterization by Western blotting using monoclonal antibodies.

Authors:  F Rotblat; D P O'Brien; F J O'Brien; A H Goodall; E G Tuddenham
Journal:  Biochemistry       Date:  1985-07-30       Impact factor: 3.162

7.  Subunit structure of thrombin-activated porcine factor VIII.

Authors:  P Lollar; C G Parker
Journal:  Biochemistry       Date:  1989-01-24       Impact factor: 3.162

8.  The contribution of Ca2+ and phospholipids to the activation of human blood-coagulation Factor X by activated Factor IX.

Authors:  K Mertens; R M Bertina
Journal:  Biochem J       Date:  1984-11-01       Impact factor: 3.857

9.  Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs.

Authors:  K M Brinkhous; H Sandberg; J B Garris; C Mattsson; M Palm; T Griggs; M S Read
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

10.  Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.

Authors:  H E Fuchs; H G Trapp; M J Griffith; H R Roberts; S V Pizzo
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

View more
  3 in total

Review 1.  Production of active eukaryotic proteins through bacterial expression systems: a review of the existing biotechnology strategies.

Authors:  Sudhir Sahdev; Sunil K Khattar; Kulvinder Singh Saini
Journal:  Mol Cell Biochem       Date:  2007-09-12       Impact factor: 3.396

2.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25

3.  Intracellular retention of a factor VIII protein with an Arg2307-->Gln mutation as a cause of haemophilia A.

Authors:  J Voorberg; R T de Laaf; P M Koster; J A van Mourik
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.